Member Comments are provided by individuals and reflect their personal opinions only. Under NO circumstances should you act on any advice or opinion posted in this forum. ALWAYS check with your personal physician before taking any action regarding your health! MedHelp International and our partners, sponsors and affiliates have no obligation to monitor any comments posted on this site, or the content and/or accuracy of such exchanges. MedHelp International does not endorse the views of any user.
Breast Cancer (Expert Forum)
IDC Treatment
Answered by
Cleveland Clinic - Breast cancer
Cleveland - OH
Questions posted in the Breast Cancer Forum are answered by medical professionals from The Cleveland Clinic. Topics include Breast Biopsy, Chemotherapy, Hormone Therapy, Lumps, Lumpectomy, Lymph node dissection, Lymphedema, Mammograms, Mastectomy, Radiation Therapy, Reconstruction, Self Breast Exam, and Surgery.
IDC Treatment
by Madi1, Aug 30, 2008 10:29PM
I had a lumpectomy 3 weeks ago for 1.5cm stage 1 grade 1 prer+ her- tumor. The local oncologist I saw Friday recommends radiation, followed by hormone therapy. I was also offered radiation since I am 46, but it not a must. I have no idea what that means, not a must. My margins were clear and no node involvement. Could you Please explain to me what this means? Do I still have cancer or is it gone with the surgery, I am very confused. Thank you so much.
Doctor's Answer
by Cleveland Clinic, Sep 02, 2008 03:37PM
, Sep 02, 2008 03:37PM
Dear Madi1, After surgery for breast cancer there are recommendations for what is called adjuvant treatment. Adjuvant treatment is treatment given to try to prevent or minimize the growth of microscopic deposits of tumor cells that might grow into a recurrent tumor.
When making recommendations for adjuvant treatment of breast cancer many factors are taken into consideration such as size of tumor, ER/PR status, Her2 status, overall health of the patient etc. After lumpectomy, radiation treatment to treat the rest of the breast is the usual treatment, but this just treats microscopic deposits of tumor cells that may be in the remaining breast tissue. In ER/PR positive breast cancers hormone therapy to suppress estrogen is common.
It could be that it was chemotherapy not radiation that was offered but is “not a must”. The decision regarding adjuvant chemotherapy would take into consideration risks and benefits to the individual patient. This is a discussion to have with the oncologist who could clarify this and discuss the risks and benefits of adjuvant chemotherapy in your specific situation. You may want to discuss with your oncologist whether a test called the “Oncotype Dx” may be helpful in making the decision about chemotherapy. This is a test that can be done on the cancer that was already removed and can help estimate the risk of future recurrence somewhere else in the body and whether chemotherapy is likely to reduce that risk. The test is most proven for cancers that are both estrogen receptor-positive and lymph node-negative.
When making recommendations for adjuvant treatment of breast cancer many factors are taken into consideration such as size of tumor, ER/PR status, Her2 status, overall health of the patient etc. After lumpectomy, radiation treatment to treat the rest of the breast is the usual treatment, but this just treats microscopic deposits of tumor cells that may be in the remaining breast tissue. In ER/PR positive breast cancers hormone therapy to suppress estrogen is common.
It could be that it was chemotherapy not radiation that was offered but is “not a must”. The decision regarding adjuvant chemotherapy would take into consideration risks and benefits to the individual patient. This is a discussion to have with the oncologist who could clarify this and discuss the risks and benefits of adjuvant chemotherapy in your specific situation. You may want to discuss with your oncologist whether a test called the “Oncotype Dx” may be helpful in making the decision about chemotherapy. This is a test that can be done on the cancer that was already removed and can help estimate the risk of future recurrence somewhere else in the body and whether chemotherapy is likely to reduce that risk. The test is most proven for cancers that are both estrogen receptor-positive and lymph node-negative.
